<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558453</url>
  </required_header>
  <id_info>
    <org_study_id>OXALI_L_04946</org_study_id>
    <nct_id>NCT01558453</nct_id>
  </id_info>
  <brief_title>Oxaliplatin for Children With Solid Tumors</brief_title>
  <official_title>Phase II Study With Oxaliplatin In Children With Relapsed/Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidnei Epelman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Santa Marcelina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pediatric neoplastic response to chemotherapy&#xD;
      proposed and evaluate sensitivity to oxaliplatin through immunohistochemistry ERCC-1&#xD;
      expression analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine pediatric neoplastic response to proposed chemotherapy. Evaluate sensitivity to oxaliplatin through immunohistochemistry ERCC-1 expression analysis.</measure>
    <time_frame>Up 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define cumulative toxicity after oxaliplatin multiple cycles in this population. Evaluate relation between time exposure to the drug (number of cycles) and response (antitumor effect x response).</measure>
    <time_frame>Up 2 years</time_frame>
    <description>Determine response time and overall survival in these patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Relapsed Solid Tumor</condition>
  <condition>Refractory Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Eloxatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.&#xD;
NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30).</description>
    <arm_group_label>Eloxatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≤ 21 years old at the time of cancer diagnosis.&#xD;
&#xD;
          2. Confirmed histological diagnosis - every patient, except brains tumor, or optic&#xD;
             pathway glioma, should have one of the following histological diagnosis:&#xD;
&#xD;
               -  Ewing´s sarcoma/PNET&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
               -  Soft tissue sarcoma/rhabdomyosarcoma&#xD;
&#xD;
               -  Wilms tumor&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  Retinoblastoma&#xD;
&#xD;
               -  Low grade astrocytoma&#xD;
&#xD;
               -  High grade astrocytoma/GBM&#xD;
&#xD;
               -  Ependymoma&#xD;
&#xD;
               -  Germ cell tumor Other rare tumors such as - hepatocellular carcinoma, pediatric&#xD;
                  colorectal carcinoma, renal cell carcinoma, adrenocortical carcinoma and&#xD;
                  nasopharyngeal carcinoma.&#xD;
&#xD;
          3. All subjects should have measurable disease, at least in one dimension, 20mm minimum,&#xD;
             or presence of neoplastic cell in cephalorachidian fluid.&#xD;
&#xD;
          4. All patients must have a life expectancy ≥ 8 weeks, with PS Karnofsky ≥50 for patients&#xD;
             with ≥ 10 years old and PS Lansky ≥50 for patients &lt; 10 years old.&#xD;
&#xD;
          5. Previous treatment:&#xD;
&#xD;
               -  at least 3 weeks without chemotherapy.&#xD;
&#xD;
               -  at least 6 months after spine and brain radiation.&#xD;
&#xD;
               -  it is allowed corticosteroids in patients with CNS tumor, but it is recommended&#xD;
                  to have stable doses or reducing the dose 7 days before protocol treatment.&#xD;
&#xD;
               -  there´s no limit of drugs or chemotherapy used previously, except oxaliplatin.&#xD;
&#xD;
          6. Adequate function as define by:&#xD;
&#xD;
               -  Hematologic: neutrophil &gt; 1000/mm³, platelet &gt; 75000/mm³ and hemoglobin &gt; 8 g/dL.&#xD;
&#xD;
               -  Renal - creatinine according to:&#xD;
&#xD;
             Age ≤ 5 anos Cr ≤ 0,8 mg/dL 5 &lt; age &lt; 10 Cr ≤ 1,0 mg/dL 10 &lt; age ≤ 15 Cr ≤ 1,2 mg/dL &gt;&#xD;
             15 years Cr ≤ 1,5 mg/dL&#xD;
&#xD;
               -  Hepatic: total bilirubin ≤ 3 mg/dL.&#xD;
&#xD;
               -  Neurologic: patients should seizure control.&#xD;
&#xD;
          7. Legal representative (father, mother or tutor) or subject (if &gt;18 years old) must sign&#xD;
             and date Informed Consent Form (ICF), after have being informed about relevant aspects&#xD;
             regarding study participation.&#xD;
&#xD;
          8. For female patients of childbearing age: Presence of a negative pregnancy test within&#xD;
             7 days prior to day 0.&#xD;
&#xD;
          9. Patient must agree in use effective contraception if procreative potential exists. Use&#xD;
             of reliable means of contraception (e.g. hormonal contraceptive, patch, vaginal ring,&#xD;
             intrauterine device, physical barrier, abstinence) for subjects of reproductive&#xD;
             potential (males and females) is required during study treatment and for 3 months&#xD;
             following last dose of study drug&#xD;
&#xD;
         10. It should not have known curative treatment option and no proved therapy that&#xD;
             increased survival with quality of life.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Oxaliplatin previous use.&#xD;
&#xD;
          2. Another chemotherapy or experimental drug, simultaneously.&#xD;
&#xD;
          3. If female, pregnant or lactating.&#xD;
&#xD;
          4. Active infection.&#xD;
&#xD;
          5. Any serious existent condition that could affect, in adverse way, subjet's capacity to&#xD;
             be treat according to protocol.&#xD;
&#xD;
          6. Any condition, therapy, or medical condition, which, in the opinion of the attending&#xD;
             physician could represent a risk for the patient or adversely affect the study&#xD;
             objectives.&#xD;
&#xD;
          7. Use of investigational drug &lt; 30 days before entering study.&#xD;
&#xD;
          8. Medical history with:&#xD;
&#xD;
               -  severe renal insufficiency;&#xD;
&#xD;
               -  known hypersensitiveness to platine;&#xD;
&#xD;
               -  myelosuppression;&#xD;
&#xD;
               -  peripheral sensory neuropathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidnei Epelman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Santa Marcelina Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Santa Marcelina Hospital</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>08270070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>March 16, 2012</study_first_submitted>
  <study_first_submitted_qc>March 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Santa Marcelina</investigator_affiliation>
    <investigator_full_name>Sidnei Epelman</investigator_full_name>
    <investigator_title>Director of Pediatric Oncology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

